Yu. V. Dolgopolova

Yu. V. Dolgopolova

Auto-generated profile, based on publicly available information

Yu. V. Dolgopolova

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
VРVera Рузинова
Vera Рузинова
YDYu. V. Dolgopolova
Yu. V. Dolgopolova
DPDmitry Petelin
Dmitry Petelin
OSO. Yu. Sorokina
O. Yu. Sorokina
Beatrice VolelBeatrice Volel
Beatrice Volel
In the past decades, biofeedback has become a widely adopted non-pharmacological option in the management of a variety of somatic, neurological, and psychiatric conditions. The biofeedback method is based on the associations between one’s vegetative and mental functions; during a session with the device, information about the change in his/her condition over time is “returned” to the patient as accessible audial or visual stimuli. The efficacy of biofeedback treatment may primarily be attributed to improvements in the state of the patients based on establishing an individual model of his/her best psychophysiological state, enabling effective rehabilitation activities at a rate suitable for each patient along with ensuring better awareness of the patient of his/her body functions; such an intervention is stepwise and helps sustain the patient’s motivation for success, thus affecting the pathological condition. This review describes the historical prerequisites for the development of biofeedback techniques and the principal mechanisms of their action; a brief summary of studies looking at the efficacy of this method in various somatic, neurological, and psychiatric conditions is also provided. The presented data clearly indicate that the use of biofeedback results in a decreased medication load in patients suffering from conditions such as arterial hypertension, epilepsy, ADHD, chronic pain, anxiety disorders, autism etc. while there are practically no contraindications for this method, except for acute psychosis, photosensitive epilepsy, and severe cognitive impairment. In this connection, clinical implementation of biofeedback techniques should be intensified in a variety of conditions.

14 August 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DPDmitry Petelin
Dmitry Petelin
OSO. Yu. Sorokina
O. Yu. Sorokina
AGA. N. Galiautdinova
A. N. Galiautdinova
YDYu. V. Dolgopolova
Yu. V. Dolgopolova
Beatrice VolelBeatrice Volel
Beatrice Volel
Anxiety disorders are the most common group of mental disorders. The high prevalence of anxiety disorders and their negative impact on the functioning and quality of life of patients determines the need for timely diagnosis and therapy. The review presents data on the clinical manifestations of anxiety, as well as on the main forms of anxiety disorders according to current classifications of mental disorders. An analysis is conducted on the relationship between somatic and cognitive manifestations of anxiety, explaining the difficulties in diagnosing and treating patients with a predominance of somatic symptoms. Cognitive features specific to patients with anxiety disorders are described. Approaches to the diagnosis and differential diagnosis of anxiety disorders are provided, along with information on main psychometric scales. The importance of a clinical approach in diagnosing anxiety disorders is justified, and the role of para-clinical methods in establishing a diagnosis is described. According to recent consensus documents and clinical guidelines, the first-line therapies for anxiety disorders are cognitive-behavioral therapy and the use of selective serotonin reuptake inhibitors; the basics of both methods are described. Considering current research, both approaches have drawbacks, which necessitates the use of medication with an alternative mechanism of action. One such medication is the modern multimodal anxiolytic Aviandr, which has demonstrated high effectiveness and safety in treating patients with the most severe form of anxiety disorders – generalized anxiety disorder. The main points of the review are illustrated with a clinical example of the successful use of Aviandr in a patient with generalized anxiety disorder.

30 April 2023 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
VTV. A. Tolmacheva
V. A. Tolmacheva
EDE. N. Dudnik
E. N. Dudnik
RSR. M. Shishorin
R. M. Shishorin
DPDmitry Petelin
Dmitry Petelin
VBV. E. Bezrukov
V. E. Bezrukov
Beatrice VolelBeatrice Volel
Beatrice Volel
Functional movement disorders (FMD) are widespread and have a significant negative impact on the quality of life of patients. The pathogenesis is not completely clear, but currently there is ongoing research on searching for biological markers using methods such as functional magnetic resonance imaging and electroencephalography (EEG). Objective: detection of the features of the amplitude-frequency characteristics of the readiness potential (RP) formed during FMD. Material and methods. We examined 22 patients with a clinically diagnosed FMD and 22 healthy volunteers (all participants were right-handed). Both patients and the control group underwent an EEG in Erickson's Flanker paradigm with registration of the RP. RP was recorded in the projection area of the precentral gyrus (electrodes C3/C4/C5/C6 in the standard 10–20 overlay scheme). Results. Comparative analysis of RP parameters showed the presence of significant frequency-amplitude differences between the main group and the control group in the right hemisphere in the absence of significant differences in the left hemisphere. At the same time, significant differences were demonstrated between the FMR group and the control group both in terms of the latent period (time to the onset of RP): 33.66±23.69 ms versus 276.28±176.1 ms (p<0.05), and its amplitude: -0.85±0.294 μV versus -0.35±0.26 μV (p<0.05). Conclusion. The results of the present study suggest that neurophysiological parameters such as RP can be considered as a potential diagnostic marker to improve the diagnosis of FMR.

19 April 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DPDmitry Petelin
Dmitry Petelin
SGS. S. Gerasimov
S. S. Gerasimov
YDYu. V. Dolgopolova
Yu. V. Dolgopolova
SSS. A. Semin
S. A. Semin
EVE. I. Voronova
E. I. Voronova
Anxiety disorders are among the most common forms of mental illness in the modern world, and one of the most significant is generalized anxiety disorder. This disorder is characterized by long-term, persistent, and severe anxiety about various issues, as well as numerous distressing sensations in the body, fatigue, sleep disturbances, and pain symptoms. Numerous studies have shown that untreated generalized anxiety disorder significantly reduces patients’ quality of life, increases the risk of disability, and negatively impacts the course of a number of socially and clinically significant somatic diseases. Despite the large number of developed diagnostic and therapeutic methods, managing patients with this disorder in real-world clinical practice remains a challenging task, requiring the clinician to select differentiated therapeutic interventions. According to current data, lifestyle modification recommendations, psychotherapeutic interventions (primarily cognitive behavioral therapy), and psychopharmacotherapy can be effective in treating generalized anxiety disorder. Monoamine reuptake inhibitors are the first-line psychopharmacotherapy for generalized anxiety disorder, and benzodiazepine tranquilizers have the most pronounced rapid anti-anxiety effect. However, both classes of medications are not without side effects and drawbacks, limiting their universal use in all patients with generalized anxiety disorder. This article concludes with two case reports demonstrating how the non-benzodiazepine anxiolytic original etifoxine may be a useful treatment option for generalized anxiety disorder, depending on the clinical situation, either as monotherapy or as an adjunct to a serotonin-norepinephrine reuptake inhibitor.

1 January 2025 in Psychiatry and psychopharmacotherapy
Verified
Journal Article
Closed access
NZN.A. Zabrodin
N.A. Zabrodin
ASA.V. Strukova
A.V. Strukova
EKE.R. Kafarov
E.R. Kafarov
YDYu.V. Dolgopolova
Yu.V. Dolgopolova
Differences in cognitive functioning and the internal picture of the disease between patients with unipolar and bipolar depression

8 August 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DPDmitry Petelin
Dmitry Petelin
EBE. A. Borisenko
E. A. Borisenko
YDYu. V. Dolgopolova
Yu. V. Dolgopolova
SSS. A. Semin
S. A. Semin
OSO. Yu. Sorokina
O. Yu. Sorokina
EVE. I. Voronova
E. I. Voronova
This article presents an analysis of the historical transformation of neurasthenia – from the popular “American disease” in the 19th century to exclusion from modern classifications (DSM, ICD-11). The neurologist J. Bird associated neurasthenia with “exhaustion” due to the transition from a traditional rural lifestyle to a fast-paced urban life. He was the first to describe a wide range of both mental and somatized symptoms. Later, the concept was reinterpreted in European psychiatry through the prism of intrapersonal conflicts, and in the Russian school of I.P. Pavlov’s neurasthenia was considered as an asthenic neurosis, represented by two main clinical forms: hyposthenic (with a predominance of weakness and lethargy) and hyperesthetic (with irritability and increased excitability). In ICD-10, neurasthenia remains as a diagnosis characterized by persistent fatigue from both physical and emotional stress, vegetative disorders and emotional lability, but in recent decades its diagnostic boundaries have significantly narrowed. This is due to the development of diagnostics and conceptualization of depression, anxiety and somatoform disorders, as well as the emergence of the concept of chronic fatigue syndrome, which is especially relevant in the post-covid period. In the framework of the presented study, the authors analyze the modern scientific discourse that examines the question of the clinical validity and diagnostic value of maintaining neurasthenia as an independent nosological unit in modern classifications of mental disorders. This publication also presents three clinical cases, using the example of which it will be possible to trace the main aspects of the clinical picture, differential diagnosis and approaches to the treatment of neurasthenia and related disorders.